<p>药明康德 (NYSE:MOH - 获取免费报告) 的目标价格在周四由瑞银集团的投资分析师从 145.00 美元上调至 151.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “中性”。瑞银集团的目标价格暗示该股票相较于前一交易日收盘价有 1.16% 的潜在上涨空间。</p>
<p>获取 <strong>药明康德</strong> 的提醒：</p>
<ul>
<li>为什么 Centene 股票下跌了 40% — 现在是否值得购买</li>
</ul>
<p>其他一些券商最近也对 MOH 发表了评论。杰富瑞金融集团在 12 月 16 日的研究报告中对药明康德的股票设定了 160.00 美元的目标价。德意志银行在 2 月 10 日的研究报告中对药明康德的股票设定了 109.00 美元的目标价。瑞穗证券将药明康德的目标价从 220.00 美元下调至 180.00 美元，并在周四的报告中给予该股票 “跑赢大盘” 的评级。桑福德·伯恩斯坦在 1 月 6 日的研究报告中重申了 “跑赢大盘” 的评级，并对药明康德的股票设定了 224.00 美元的目标价。最后，摩根士丹利在 3 月 4 日的研究报告中将药明康德的目标价从 158.00 美元下调至 128.00 美元，并对该公司设定了 “等权重” 的评级。两位股票研究分析师给予该股票 “买入” 评级，十位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，药明康德目前的共识评级为 “持有”，平均目标价为 153.29 美元。</p>
<p><strong>查看我们关于 MOH 的最新研究报告</strong></p>
<h2>药明康德的价格表现</h2>
<ul>
<li>在市场动荡中持平的三只健康保险股票</li>
</ul>
<p>周四午盘交易中，MOH 股票上涨了 2.47 美元，达到 149.27 美元。该股票的交易量为 1,292,356 股，而其平均交易量为 1,770,036 股。该股票的 50 日移动平均价格为 164.71 美元，200 日移动平均价格为 167.47 美元。该公司的债务与股本比率为 0.97，速动比率为 1.69，流动比率为 1.69。该股票的市值为 76.9 亿美元，市盈率为 17.44，贝塔值为 0.52。药明康德的 52 周低点为 121.06 美元，52 周高点为 359.97 美元。</p>
<p>药明康德 (NYSE:MOH - 获取免费报告) 最近在 2 月 5 日发布了其财报。该公司报告季度每股收益为（2.75 美元），低于共识预期的 0.43 美元（差距为 3.18 美元）。药明康德的净利润率为 1.04%，股本回报率为 13.60%。该公司在本季度的收入为 113.8 亿美元，而分析师预期为 109 亿美元。去年同期，该公司每股收益为 5.05 美元。该公司的季度收入同比增长了 8.3%。药明康德已将其 2026 财年的指导目标设定为 5.000-每股收益。研究分析师预测药明康德在当前年度的每股收益将达到 24.4 美元。</p>
<h2>对药明康德的对冲基金看法</h2>
<ul>
<li>这三只医疗股票的势头正在增长</li>
</ul>
<p>几家机构投资者和对冲基金最近修改了对 MOH 的持股。AQR Capital Management LLC 在第三季度将其在药明康德的持股增加了 217.0%。AQR Capital Management LLC 目前拥有 2,934,130 股该公司的股票，价值 561,475,000 美元，此前在上个季度增持了 2,008,458 股。8 Knots Management LLC 在第四季度收购了药明康德的新股份，价值 198,942,000 美元。胜利资本管理公司在第三季度将其在药明康德的持股增加了 344.3%。胜利资本管理公司目前拥有 963,526 股该公司的股票，价值 184,380,000 美元，此前在上个季度增持了 746,639 股。挪威银行在第二季度购买了药明康德的新股份，价值 212,113,000 美元。最后，麦迪逊大道合伙公司在第四季度购买了药明康德的新股份，价值 110,003,000 美元。对冲基金和其他机构投资者持有该公司 98.50% 的股票。</p>
<h2>药明康德公司简介</h2>
<p>(获取免费报告)</p>
<p>药明康德公司是一家专注于政府资助的健康保险计划的管理医疗公司。该公司提供医疗补助管理医疗计划、医疗保险优势和处方药计划，以及根据《平价医疗法案》提供的个人市场计划。通过综合护理模式，药明康德强调预防和初级护理服务、护理协调和疾病管理，以改善其成员的健康结果。</p>
<p>该公司的根源可以追溯到 1980 年代初，当时博士。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过药明康德</li>
<li>20 万亿美元的发现潜藏在海洋之下</li>
<li>AI CEO 发布红色警报：准备迎接崩溃</li>
<li>黄金的大幅波动可能正在创造早期机会</li>
<li>历史上最大的首次公开募股即将到来</li>
<li>埃隆·马斯克的 1 万亿美元 AI 首次公开募股</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0V_U3ltYm9sPU1PSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0V_U3ltYm9sPU1PSA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在药明康德吗？</h2>
<p>在你考虑药明康德之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而药明康德并不在名单上。</p>
<p>虽然 Molina 医疗目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Molina医疗

美国医疗保健供应商 ETF - iShares

标普医疗保健服务 ETF - SPDR

医疗业 3 倍做多 - Direxion

2 倍做空卫生保健 ETF - ProShares

<p>瑞士银行集团已将 Molina Healthcare（纽约证券交易所代码：MOH）的目标价格从 145.00 美元上调至 151.00 美元，维持 “中性” 评级。这表明该股票相较于前一交易日收盘价有 1.16% 的潜在上涨空间。其他分析师的观点各异，目标价格范围从 109.00 美元到 224.00 美元不等。Molina Healthcare 的股票最近交易价格为 149.27 美元，市值为 76.9 亿美元。该公司报告上个季度的收入为 113.8 亿美元，超出预期，但未能达到盈利预期。机构投资者持有该公司 98.50% 的股份</p>

<p>Molina Healthcare (NYSE:MOH - Get Free Report) had its target price boosted by investment analysts at UBS Group from $145.00 to $151.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a &#34;neutral&#34; rating on the stock. UBS Group's price target would suggest a potential upside of 1.16% from the stock's previous close.</p>
<div class="lb-trans"><p>药明康德 (NYSE:MOH - 获取免费报告) 的目标价格在周四由瑞银集团的投资分析师从 145.00 美元上调至 151.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “中性”。瑞银集团的目标价格暗示该股票相较于前一交易日收盘价有 1.16% 的潜在上涨空间。</p>
</div><p>Get <strong>Molina Healthcare</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>药明康德</strong> 的提醒：</p>
</div><ul>
<li>Why Centene Stock Dropped 40% — And Whether It's a Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 Centene 股票下跌了 40% — 现在是否值得购买</li>
</ul>
</div><p>A number of other brokerages have also recently commented on MOH. Jefferies Financial Group set a $160.00 price objective on shares of Molina Healthcare in a research note on Tuesday, December 16th. Deutsche Bank Aktiengesellschaft set a $109.00 target price on shares of Molina Healthcare in a research report on Tuesday, February 10th. Mizuho reduced their price target on shares of Molina Healthcare from $220.00 to $180.00 and set an &#34;outperform&#34; rating on the stock in a report on Thursday. Sanford C. Bernstein reiterated an &#34;outperform&#34; rating and issued a $224.00 price target on shares of Molina Healthcare in a research report on Tuesday, January 6th. Finally, Morgan Stanley dropped their price objective on shares of Molina Healthcare from $158.00 to $128.00 and set an &#34;equal weight&#34; rating for the company in a research note on Wednesday, March 4th. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Molina Healthcare presently has a consensus rating of &#34;Hold&#34; and an average price target of $153.29.</p>
<div class="lb-trans"><p>其他一些券商最近也对 MOH 发表了评论。杰富瑞金融集团在 12 月 16 日的研究报告中对药明康德的股票设定了 160.00 美元的目标价。德意志银行在 2 月 10 日的研究报告中对药明康德的股票设定了 109.00 美元的目标价。瑞穗证券将药明康德的目标价从 220.00 美元下调至 180.00 美元，并在周四的报告中给予该股票 “跑赢大盘” 的评级。桑福德·伯恩斯坦在 1 月 6 日的研究报告中重申了 “跑赢大盘” 的评级，并对药明康德的股票设定了 224.00 美元的目标价。最后，摩根士丹利在 3 月 4 日的研究报告中将药明康德的目标价从 158.00 美元下调至 128.00 美元，并对该公司设定了 “等权重” 的评级。两位股票研究分析师给予该股票 “买入” 评级，十位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，药明康德目前的共识评级为 “持有”，平均目标价为 153.29 美元。</p>
</div><p><strong>View Our Latest Research Report on MOH</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 MOH 的最新研究报告</strong></p>
</div><h2>Molina Healthcare Price Performance</h2>
<div class="lb-trans"><h2>药明康德的价格表现</h2>
</div><ul>
<li>3 Health Insurance Stocks Holding Green in Market Turmoil</li>
</ul>
<div class="lb-trans"><ul>
<li>在市场动荡中持平的三只健康保险股票</li>
</ul>
</div><p>MOH stock traded up $2.47 during midday trading on Thursday, hitting $149.27. 1,292,356 shares of the stock were exchanged, compared to its average volume of 1,770,036. The stock's 50-day moving average price is $164.71 and its 200-day moving average price is $167.47. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.69 and a current ratio of 1.69. The stock has a market cap of $7.69 billion, a price-to-earnings ratio of 17.44 and a beta of 0.52. Molina Healthcare has a fifty-two week low of $121.06 and a fifty-two week high of $359.97.</p>
<div class="lb-trans"><p>周四午盘交易中，MOH 股票上涨了 2.47 美元，达到 149.27 美元。该股票的交易量为 1,292,356 股，而其平均交易量为 1,770,036 股。该股票的 50 日移动平均价格为 164.71 美元，200 日移动平均价格为 167.47 美元。该公司的债务与股本比率为 0.97，速动比率为 1.69，流动比率为 1.69。该股票的市值为 76.9 亿美元，市盈率为 17.44，贝塔值为 0.52。药明康德的 52 周低点为 121.06 美元，52 周高点为 359.97 美元。</p>
</div><p>Molina Healthcare (NYSE:MOH - Get Free Report) last posted its earnings results on Thursday, February 5th. The company reported ($2.75) earnings per share for the quarter, missing the consensus estimate of $0.43 by ($3.18). Molina Healthcare had a net margin of 1.04% and a return on equity of 13.60%. The firm had revenue of $11.38 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same period last year, the company posted $5.05 EPS. The firm's revenue for the quarter was up 8.3% on a year-over-year basis. Molina Healthcare has set its FY 2026 guidance at 5.000- EPS. Research analysts predict that Molina Healthcare will post 24.4 earnings per share for the current year.</p>
<div class="lb-trans"><p>药明康德 (NYSE:MOH - 获取免费报告) 最近在 2 月 5 日发布了其财报。该公司报告季度每股收益为（2.75 美元），低于共识预期的 0.43 美元（差距为 3.18 美元）。药明康德的净利润率为 1.04%，股本回报率为 13.60%。该公司在本季度的收入为 113.8 亿美元，而分析师预期为 109 亿美元。去年同期，该公司每股收益为 5.05 美元。该公司的季度收入同比增长了 8.3%。药明康德已将其 2026 财年的指导目标设定为 5.000-每股收益。研究分析师预测药明康德在当前年度的每股收益将达到 24.4 美元。</p>
</div><h2>Hedge Funds Weigh In On Molina Healthcare</h2>
<div class="lb-trans"><h2>对药明康德的对冲基金看法</h2>
</div><ul>
<li>Momentum Grows for These 3 Healthcare Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>这三只医疗股票的势头正在增长</li>
</ul>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of MOH. AQR Capital Management LLC raised its holdings in Molina Healthcare by 217.0% in the 3rd quarter. AQR Capital Management LLC now owns 2,934,130 shares of the company's stock valued at $561,475,000 after acquiring an additional 2,008,458 shares during the last quarter. 8 Knots Management LLC acquired a new stake in shares of Molina Healthcare during the fourth quarter worth $198,942,000. Victory Capital Management Inc. boosted its holdings in shares of Molina Healthcare by 344.3% during the third quarter. Victory Capital Management Inc. now owns 963,526 shares of the company's stock worth $184,380,000 after purchasing an additional 746,639 shares during the last quarter. Norges Bank purchased a new stake in shares of Molina Healthcare in the second quarter valued at $212,113,000. Finally, Madison Avenue Partners LP purchased a new stake in shares of Molina Healthcare in the fourth quarter valued at $110,003,000. Hedge funds and other institutional investors own 98.50% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近修改了对 MOH 的持股。AQR Capital Management LLC 在第三季度将其在药明康德的持股增加了 217.0%。AQR Capital Management LLC 目前拥有 2,934,130 股该公司的股票，价值 561,475,000 美元，此前在上个季度增持了 2,008,458 股。8 Knots Management LLC 在第四季度收购了药明康德的新股份，价值 198,942,000 美元。胜利资本管理公司在第三季度将其在药明康德的持股增加了 344.3%。胜利资本管理公司目前拥有 963,526 股该公司的股票，价值 184,380,000 美元，此前在上个季度增持了 746,639 股。挪威银行在第二季度购买了药明康德的新股份，价值 212,113,000 美元。最后，麦迪逊大道合伙公司在第四季度购买了药明康德的新股份，价值 110,003,000 美元。对冲基金和其他机构投资者持有该公司 98.50% 的股票。</p>
</div><h2>Molina Healthcare Company Profile</h2>
<div class="lb-trans"><h2>药明康德公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Molina Healthcare, Inc is a managed care company specializing in government-sponsored health insurance programs. The company offers Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care model, Molina emphasizes preventive and primary care services, care coordination, and disease management to improve health outcomes for its members.</p>
<div class="lb-trans"><p>药明康德公司是一家专注于政府资助的健康保险计划的管理医疗公司。该公司提供医疗补助管理医疗计划、医疗保险优势和处方药计划，以及根据《平价医疗法案》提供的个人市场计划。通过综合护理模式，药明康德强调预防和初级护理服务、护理协调和疾病管理，以改善其成员的健康结果。</p>
</div><p>The company traces its roots to the early 1980s, when Dr.</p>
<div class="lb-trans"><p>该公司的根源可以追溯到 1980 年代初，当时博士。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Molina Healthcare</li>
<li>The $20 Trillion Discovery Beneath the Waves</li>
<li>AI CEO Issues Code Red: Prepare for Meltdown</li>
<li>Gold's Big Move May Be Creating Early Opportunities</li>
<li>The largest IPO in history is coming</li>
<li>Elon Musk’s $1 Quadrillion AI IPO</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过药明康德</li>
<li>20 万亿美元的发现潜藏在海洋之下</li>
<li>AI CEO 发布红色警报：准备迎接崩溃</li>
<li>黄金的大幅波动可能正在创造早期机会</li>
<li>历史上最大的首次公开募股即将到来</li>
<li>埃隆·马斯克的 1 万亿美元 AI 首次公开募股</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1PSA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=MOH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Molina Healthcare Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在药明康德吗？</h2>
</div><p>Before you consider Molina Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑药明康德之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molina Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而药明康德并不在名单上。</p>
</div><p>While Molina Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Molina 医疗目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

瑞银集团预测 Molina 医疗（NYSE:MOH）股票将出现强劲的价格升值